Regeneron Pharmaceuticals, Inc. (REGN) is expected to report earnings on Wednesday, October 28, 2026, after the close. Estimated release time 06:51 ET. Consensus EPS estimate is $16.00.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $10.16 | $14.29 | +40.6% | $4.29B |
| 2026-04-29 | FY2026 Q1 | $8.91 | $9.47 | +6.3% | $3.61B |
| 2026-01-30 | FY2025 Q4 | $10.74 | $11.44 | +6.5% | $3.88B |
| 2025-10-28 | FY2025 Q3 | $9.65 | $11.83 | +22.6% | $3.75B |
| 2025-08-01 | FY2025 Q2 | $8.43 | $12.89 | +52.9% | $3.68B |
| 2025-04-29 | FY2025 Q1 | $8.62 | $8.22 | -4.6% | $3.03B |
| 2025-02-04 | FY2024 Q4 | $11.21 | $12.07 | +7.7% | $3.79B |
| 2024-10-31 | FY2024 Q3 | $11.69 | $12.46 | +6.6% | $3.72B |
REGN has beaten consensus EPS in 7 of its last 8 reported quarters.
See REGN on the live calendar →